07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

Pulmagen, Teijin deal

Pulmagen granted Teijin exclusive rights to develop and commercialize ADC3680 in Japan. Teijin plans to start Phase I testing of ADC3680 in Japan in April 2013 for asthma. The oral small molecule prostaglandin D2...
01:09 , Sep 27, 2012 |  BC Extra  |  Company News

Teijin receives Japanese rights to Pulmagen's asthma product

Pulmagen Therapeutics Ltd. (Slough, U.K.) granted Teijin Pharma Ltd. (Tokyo, Japan) exclusive rights in Japan to develop and commercialize asthma product ADC3680. Teijin plans to start Phase I testing of ADC3680 in Japan in April...